PharmaPoint: Venous Thromboembolism – Global Drug Forecast and Market Analysis to 2026

2017-06-01
Price :
Published : Jun-2017
No. of Pages : 203

PharmaPoint: Venous Thromboembolism – Global Drug Forecast and Market Analysis to 2026

Summary

Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from pulmonary embolism (PE) to deep vein thrombosis (DVT). The therapeutic landscape for VTE is divided into the VTE treatment setting and VTE primary prophylaxis, which is further divided into the prophylaxis for total knee replacement (TKR) and total hip replacement (THR) patients, as well as for acute medically ill patients. Antithrombotic therapy represents the cornerstone treatment strategy for all VTE patients. Presently, the established vitamin K antagonists (VKA) and low molecular weight heparins (LMWH) are the most widely prescribed drugs for VTE treatment and prophylaxis, where the historical dominance of these therapies has been the most prominent barrier towards VTE market evolution and growth.

It is estimated that sales of venous thromboembolism (VTE) therapeutics were approximately $1.95B across the seven major markets (7MM) in 2016, which includes the US, the five major European markets (5EU: France, Germany, Italy, Spain, and UK), and Japan. In the 2016 base year, 25% of market shares were attributed to the VTE treatment setting ($497M) and 75% to VTE primary prophylaxis treatments ($1.45B).

By 2026, it is expected that the VTE market to grow at a strong Compound Annual Growth Rate (CAGR) of 3.87%, reaching sales of $2.85B by the end of the forecast period. The main market contributing to the sustained growth over this forecast is the US, contributing $1.43B in sales in 2016, a figure that is anticipated to increase at a CAGR of 3.08% to $1.94B by 2026. Over this forecast, the most prominent wave of sales increases comes from the novel oral anticoagulant (NOAC) class, which is expected to peak at $1.04B in global sales by 2022, reflecting a 10-year CAGR of 3.91% by 2026, despite the generic erosion of several key players.

Major drivers of VTE market growth over the forecast period are the –
– Increase in patient shares towards the NOACs due to increased confidence among physicians about using these novel therapies.
– Launch of betrixaban for extended-duration prophylaxis in acute medically ill patients.
– Launch of the first Factor XI inhibitor, IONIS-FXIRX.
– Increase in the global prevalence of VTE.
– Launch of the Factor Xa reversal agents.

Major growth in the VTE market over the forecast period is caused by the rise in sales surrounding the VTE primary prophylaxis space, which increased from $1.45B in 2016 to $2.3B by 2026 at a CAGR of 4.66%. The VTE prophylaxis segment dominates the VTE space due to the much higher number of patients in need of prophylaxis compared to the number of patients in need of VTE treatment.

The report “PharmaPoint: Venous Thromboembolism – Global Drug Forecast and Market Analysis to 2026” provides an Overview of VTE, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

In depth, this report provides the following –
– Annualized VTE therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
– Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the VTE therapeutics market.
– Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
– Analysis of the current and future market competition in the global VTE therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned in this report: Boehringer Ingelheim, Bayer, Janssen, BMS, Pfizer, Sanofi, Daiichi-Sankyo, Portola Pharmaceuticals, Ionis Therapeutics, Armetheon.

Scope

– Overview of VTE, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
– Annualized VTE therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
– Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the VTE therapeutics market.
– Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
– Analysis of the current and future market competition in the global VTE therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to –
– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
– Develop business strategies by understanding the trends shaping and driving the global VTE therapeutics market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global VTE therapeutics market in future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
– Track drug sales in the global VTE therapeutics market from 2016-2026.
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Filed in: Pharmaceutical
Publisher : GlobalData
More Reports
Title Price Buy Now

Alzheimer’s Disease: Global Drug Forecast and Market Analysis to 2028

Alzheimer's Disease: Global Drug Forecast and Market Analysis to 2028 Summary Alzheimer's disease (AD) is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline. During the early stages of the disease, sleep disturbances and forgetfulness are generally the first presenting symptoms. In the severe stages, patients with AD require permanent observation, either by a home care professional or a family member. The rapidly declining status of patients with AD results in a drastic reduction in quality of life (QOL) for both patients and their caretakers. With rapidly increasing worldwide prevalence, AD has been identified as a major global health threat by the international medical community. Significant efforts have been made ......
$10995

Epidemiology Analysis and Forecast: Coronavirus Disease (COVID-19) – May 2020

Epidemiology Analysis and Forecast: Coronavirus Disease (COVID-19) - May 2020 Summary The report provide forecast for peak-week and return-to-normal week that will help the reader plan in this uncertain time, and highlights important populations and regions most affected by the outbreak. The report covers current epidemiology situation, forecast, and analysis of COVID-19 in May 2020, including forecast for key markets.The report will be updated on a monthly basis. First reported in Wuhan, China, in December 2019, now more than 846,200 confirmed cases of COVID-19 are spread across 187 countries worldwide. The US and several countries in Europe such as Italy, Spain, and Belgium have continued to see a decrease in daily cases. Russia, Brazil, and Latin American countries are seeing increa......
$1995

Dry Eye Syndrome: Global Drug Forecast and Market Analysis to 2028

Dry Eye Syndrome: Global Drug Forecast and Market Analysis to 2028 Summary Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS), is a multifactorial disease of the tears and ocular surface that causes ocular discomfort, visual disturbances, and tear film instability, which can potentially damage the ocular surface. The DES market has had few new therapeutics in the last decade. However, the current treatment landscape is anticipated to witness a dramatic progress with the expected launch of numerous pipeline DES drugs during the forecast period, which will be a significant driver of growth in the 9MM. Anticipated to be a lucrative market given that its prevalence is expected to increase during the forecast period as well as a significant need to introduce new therapy ......
$10995

Myelodysplastic Syndromes: Opportunity Analysis and Forecasts to 2028

Myelodysplastic Syndromes: Opportunity Analysis and Forecasts to 2028 Summary Myelodysplastic syndromes (MDS) are a relatively rare group of acquired clonal hematopoietic stem cell disorders characterized by dysfunctional hematopoiesis leading to cytopenias, with the potential to transform into acute myeloid leukemia (AML). DNA damage and mutations are the predominant factors contributing to MDS development and progression. As such, aging and the associated accumulation of mutations over time appear to be the most important risk factors for the disease. Clonal shifts in hematopoietic stem and progenitor cells due to mutations, cytogenetic alterations, and modified epigenetic marks can promote the expansion of abnormal, dysfunctional cells. In symptomatic MDS, these cellular changes manif......
$10995

Immunotherapy Drugs Market by Type (Monoclonal Antibodies, Check Point Inhibitors, Interferons, and Interleukins), Therapy Area (Cancer, Autoimmune diseases& Inflammatory, Infectious Diseases), End User (Hospitals, Clinics ) – Global Forecast to 2025

 “The immunotherapy drugs market is projected to grow at a CAGR of 11.0% during the forecast period (2020–2025).” The global immunotherapy drugs market is projected to reach USD 274.6 billion by 2025 from USD 163.0 billion in 2020, at a CAGR of 11.0 % during the forecast period. Market growth is primarily driven by the rising demand for immunotherapies over conventional treatments and a growing prevalence of target indications. However, timeline issues, side-effects, and manufacturing complexities are expected to restrict market growth to a certain extent. “Monoclonal antibodies are expected to witness high demand during the forecast period.” The adoption of immunotherapy in cancer has been rising in recent years due to the introduction of safe and efficient treatments.......
$4950

Alzheimer’s Disease: Epidemiology Forecast to 2028

Alzheimer's Disease: Epidemiology Forecast to 2028 Summary Alzheimer's Disease (AD) is a subtype of dementia and is an irreversible, neurodegenerative brain disease of the elderly. AD is characterized by the death of brain cells, which leads to a progressive decline in memory and cognitive abilities including thinking, language, and learning capacity (National Institute on Aging, 2019). AD is the most common type of dementia (Centers for Disease Control and Prevention, 2019). GlobalData epidemiologists utilized county-specific studies published in peer-reviewed journals as well as medical record review studies to build the forecast. The disease definition for AD was based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Revised (DSM-IV) and the National Institu......
$3995

Myelodysplastic Syndrome: Epidemiology Forecast to 2028

Myelodysplastic Syndrome: Epidemiology Forecast to 2028 Summary MDS are rare and a diverse group of clonal hematopoietic malignancies characterized by cytogenetic and molecular abnormalities, causing bone marrow failure and risk of progression to AML. MDS can affect people of any age but usually is most common in the 70 years and older population, with approximately 86% of newly diagnosed cases in older population over the age of 60 years. MDS patients present with symptoms related to peripheral cytopenias, though they may also be asymptomatic and routine laboratory findings might not detect anything significant except abnormal blood counts. GlobalData epidemiologists used age- and sex-specific diagnosed incidence and prevalence rates to forecast the diagnosed incident and prevalent ca......
$3995

Social Media: Coronavirus Disease (COVID-19) Sector Impact

Social Media: Coronavirus Disease (COVID-19) Sector Impact Summary The highly contagious coronavirus (SARS-CoV-2), dubbed COVID-19 (formerly 2019-nCoV), which emerged at the close of 2019, has led to a medical emergency across the world, with the World Health Organization (WHO) officially declaring the novel coronavirus a pandemic on March 11, 2020. This report analyzes GlobalData's social media Influencer dashboards to understand Influencer trends since the pandemic began and what key Influencers are discussing online about COVID-19. Scope - This report analyzes Influencer trends since the pandemic began and what assesses what key Influencers are discussing online about the virus. - The report includes 10 Influencer dashboards: - Eight therapy areas: Cardiovascular, Metabolic Disord......
$995

Ambulatory Surgical Centers Market by Product (EHR, Practice Management, Telehealth, Healthcare Analytics, PHM, Supply Chain Management, RCM, Surgical planning, Quality Management), Specialty Type (Single, Multi-specialty) – Global Forecast to 2025

The Ambulatory Surgical Centers market is projected to reach USD 7.2 billion by 2025 from 2.1 billion in 2020 at a CAGR of 27.6% during the forecast period.There is a growing inclination across the globe towards the adoption of healthcare IT technologies due to the increasing need to deliver quality care to patients while curtailing escalating healthcare costs. These robust IT solutions are designed to streamline workflow in healthcare systems, reduce expenses, and facilitate compliance with stringent regulatory guidelines. By-products and services, the healthcare providers segment accounted for the largest share of the Ambulatory Surgical Centers market in 2018 Based on products and services, the Ambulatory Surgical Centers market is segmented into healthcare provider solutions, h......
$5650

Coronavirus Disease (COVID-19) Sector Impact: Health Insurance Implications – May 2020

Coronavirus Disease (COVID-19) Sector Impact: Health Insurance Implications - May 2020 Summary The highly contagious coronavirus (SARS-CoV-2), dubbed COVID-19 (formerly 2019-nCoV), which emerged at the close of 2019, has led to a medical emergency across the world, with the World Health Organization (WHO) officially declaring the novel coronavirus a pandemic on March 11, 2020. The virus is also having a growing impact on the global economy including the health insurance industry. This report reflects how government bodies and healthcare authorities are reacting to protect policyholder interest and minimize the impact on the health insurance industry during the COVID-19 crisis. Scope - This report reflects how government bodies and healthcare authorities are reacting to protect policyh......
$495
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy